# US 2022/0031853 A1 · Hsp90-targeting conjugates and formulations thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031853 A1
- Document ID: US20220031853A1
- Status: Published application
- Kind: A1
- Application number: 17/275,748
- Filed: 2019-09-13
- Published: 2022-02-03
- Earliest claimed: 2018-09-14
- Assignees: Tarveda Therapeutics, Inc.
- Applicants: Tarveda Therapeutics, Inc.
- Inventors: Brian H. WHITE; Benoît MOREAU; Tyler CIPRIANI; Mark T. BILODEAU
- Web page: https://patentgrep.com/patent/US20220031853A1

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/552: {one of the codrug's components being an antibiotic}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

## Claims

### Claim 1

A conjugate comprising an active agent coupled, via a linker, to an HSP90 targeting moiety, wherein the active agent is a PI3K inhibitor and wherein the PI3K inhibitor is selected from the group consisting of BGT-226 (NVP-BGT226), PF-05212384, PF-04691502, and fragments/derivatives/analogs thereof.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the HSP90 targeting moiety is an HSP90 inhibitor.

### Claim 3 (depends on 2)

The conjugate of claim 2, wherein the HSP90 inhibitor is a small molecule.

### Claim 4 (depends on 3)

The conjugate of claim 3, wherein the HSP90 inhibitor is selected from the group consisting of Ganetespib, Luminespib (AUY-922, NVP-AUY922), Debio-0932, MPC-3100, or Onalespib (AT-13387), SNX-2112, 17-amino-geldanamycin hydroquinone, PU-H71, AT13387, and derivatives/analogs thereof.

### Claim 5 (depends on 1)

The conjugate of claim 1, wherein the HSP90 targeting moiety is ganetespib or a derivative thereof.

### Claim 6 (depends on 1)

The conjugate of claim 1, wherein the HSP90 targeting moiety comprises a structure of

### Claim 7 (depends on 1)

The conjugate of claim 1, wherein the linker comprises an ester group, a disulfide group, an amide group, an acylhydrazone group, an ether group, a carbamate group, a carbonate group, or an urea group.

### Claim 8 (depends on 1)

The conjugate of claim 1, wherein the linker is a cleavable linker.

### Claim 9 (depends on 1)

The conjugate of claim 1, wherein the conjugate has a molecular weight of less than about 50,000 Da, less than about 40,000 Da, less than about 30,000 Da, less than about 20,000 Da, less than about 15,000 Da, less than about 10,000 Da, less than about 8,000 Da, less than about 5,000 Da, less than about 3,000 Da, less than 2000 Da, less than 1500 Da, less than 1000 Da, or less than 500 Da.

### Claim 10 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises PF-05212384 or its fragment/derivative/analog and ganetespib or its derivative.

### Claim 11 (depends on 10)

The conjugate of claim 10, wherein the conjugate is selected from the group consisting of Conjugate 18, Conjugate 19, Conjugate 20, and Conjugate 21, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The conjugate of claim 1, wherein the conjugate comprises BGT-226 or its fragment/derivative/analog and ganetespib or its derivative.

### Claim 13 (depends on 12)

The conjugate of claim 12, wherein the conjugate is selected from the group consisting of Conjugate 22, Conjugate 23, Conjugate 24, Conjugate 25, and Conjugate 26, or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The conjugate of claim 1, further comprising a permeability modulating unit.

### Claim 15 (depends on 1)

The conjugate of claim 1, further comprising a pharmacokinetic modulating unit.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising the conjugate of claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 17 (depends on 1)

A method of reducing cell proliferation comprising administering a therapeutically effective amount of at least one conjugate of claim 1 to the cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cell is a cancer cell.

### Claim 19 (depends on 18)

The method of claim 18, wherein the cancer cell is a small-cell lung cancer cell, a non-small-cell lung cancer cell, a sarcoma cell, a pancreatic cancer cell, a breast cancer cell, or a colon cancer cell.

### Claim 20 (depends on 16)

A method of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 16.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cancer is small-cell lung cancer cell, a non-small-cell lung cancer cell, a sarcoma cell, a pancreatic cancer cell, a breast cancer cell, or a colon cancer cell.
